1,086 material Form 8-K filings that 883 companies we cover made with the SEC in July 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Quaker Houghton reported second-quarter 2025 net sales of $483.4 million, up 4% from a year earlier, but posted a net loss of $66.6 million, or $3.78 per diluted share, driven by an $88.8 million non-cash goodwill impairment tied to its EMEA segment. Non-GAAP earnings per diluted share fell to $1.71 from $2.13, and management expects a stronger second half with full-year 2025 revenue and earnings in the range of 2024.
Net sales rose 4% to $483.4 million from $463.6 million, with organic sales volumes up 2%.
Net loss of $66.6 million, or $3.78 per diluted share, compared with net income of $34.9 million a year earlier.
Non-GAAP earnings per diluted share were $1.71 versus $2.13; adjusted EBITDA was $75.5 million, down about 10%.
Management expects full-year 2025 revenue and earnings in the range of 2024 and about $20 million of run-rate cost savings by the end of 2026.
Ingersoll Rand reported second quarter 2025 revenue of $1,888 million, up 5%, and raised its full-year 2025 revenue, Adjusted EBITDA and Adjusted EPS guidance. The company also reported a net loss attributable to Ingersoll Rand of $115 million, or $0.29 per share, driven by $265.8 million of non-cash impairments that it says do not affect adjusted earnings. For shareholders, the higher guidance is offset by the reported loss and by Adjusted EPS of $0.80, down from $0.83 a year earlier.
Revenue of $1,888 million, up 5%; orders of $1,940 million, up 8%
Reported net loss attributable to Ingersoll Rand of $115 million, or $0.29 per share, including $265.8 million of goodwill and intangible asset impairments
Adjusted EPS of $0.80 versus $0.83 a year earlier; Adjusted EBITDA of $509 million, up 3%
2025 guidance raised: Adjusted EBITDA of $2,100 million to $2,160 million and Adjusted EPS of $3.34 to $3.46
Camden Property Trust reported second-quarter 2025 EPS of $0.74, up from $0.40 a year earlier, but the filing says about $0.43 per share came from a gain on sale of an operating property. Core FFO per diluted share was $1.70, down from $1.71, and the company raised its 2025 Core FFO guidance to $6.76 to $6.86 from a prior midpoint of $6.78.
Q2 2025 EPS $0.74 vs. $0.40 in Q2 2024; EPS included about $0.43 per share from a gain on sale of an operating property
Q2 2025 Core FFO $1.70 vs. $1.71 a year earlier; Core AFFO $1.43 vs. $1.44
Q2 2025 property revenues $396.5 million vs. $387.2 million in Q2 2024
2025 Core FFO guidance $6.76 to $6.86 (midpoint $6.81, up $0.03); 2025 EPS guidance $2.33 to $2.43
World Kinect reported a GAAP net loss attributable to the company of $339 million, or $6.06 per diluted share, for the second quarter of 2025, compared with net income of $108 million, or $1.81 per share, a year earlier. The loss reflects $367 million of non-cash Land segment intangible asset impairments, including $359 million of goodwill, and an $82 million pre-tax loss on the sale of its U.K. land fuels business, while revenue fell 18% to $9.04 billion and adjusted diluted EPS rose 23% to $0.59.
Revenue was $9.04 billion, down 18% from $10.97 billion a year earlier; gross profit was $232 million, down 5%.
GAAP net loss attributable to World Kinect was $339 million, or $6.06 per diluted share, versus net income of $108 million, or $1.81 per share, in the second quarter of 2024.
Adjusted diluted EPS was $0.59, up 23% from $0.48; the company repurchased $35 million of common stock in the quarter.
The Land segment recorded $367 million of intangible asset impairments, and the U.K. land fuels business sale was completed on April 9, 2025.
DXC Technology reported first quarter fiscal 2026 revenue of $3.16 billion, down 2.4% year over year, and diluted EPS of $0.09, down 35.7%. The company raised its full-year fiscal 2026 non-GAAP diluted EPS guidance to $2.85 to $3.35 from $2.75 to $3.25, while revenue and reported profit declined for the quarter.
Total revenue was $3.16 billion, down 2.4% year over year and down 4.3% on an organic basis
Diluted EPS was $0.09 versus $0.14 a year earlier; non-GAAP diluted EPS was $0.68, down 9.3%
Full-year fiscal 2026 non-GAAP diluted EPS guidance raised to $2.85 to $3.35 from $2.75 to $3.25
Bookings were $2.8 billion, up 14% year over year, and the company repurchased $50 million of shares
Healthcare Realty reported a second-quarter GAAP net loss of $0.45 per share, wider than the $0.39 loss a year earlier, while normalized FFO rose to $0.41 per share from $0.38 and the company raised its 2025 normalized FFO guidance by one cent at the midpoint. The board also cut the common dividend 23% to $0.24 per share, which the company said reduces the FAD payout ratio to approximately 80%. New CEO Peter Scott, who joined April 15, is leading a strategic plan and platform restructuring.
GAAP net loss attributable to common stockholders was $157.9 million, or $(0.45) per share, versus $143.8 million, or $(0.39) per share, in the second quarter of 2024
Normalized FFO was $0.41 per share versus $0.38 a year earlier; 2025 normalized FFO guidance rose to $1.57 to $1.61 from $1.56 to $1.60
Quarterly common dividend of $0.24 per share, payable August 28, 2025, to holders of record on August 14, 2025
Peter Scott joined as President and CEO on April 15, 2025; the board was reduced from 12 to 7 members
Reinsurance Group of America reported second-quarter 2025 net income of $180 million, or $2.70 per diluted share, down from $203 million, or $3.03, a year earlier, while net premiums rose 5.9% to $4.2 billion. CEO Tony Cheng said results were below expectations, mainly due to claims volatility in U.S. Individual Life, and the company also raised its quarterly dividend 4.5% to $0.93 and entered reinsurance agreements covering about $32 billion of Equitable Holdings life insurance liabilities.
Net income available to RGA shareholders was $180 million ($2.70 per diluted share) versus $203 million ($3.03) a year earlier.
Adjusted operating income was $315 million ($4.72 per diluted share) versus $365 million ($5.48).
Quarterly dividend increased 4.5% to $0.93 per share, payable August 26, 2025, to holders of record as of August 12, 2025.
RGA Re ceded a 75% quota share of Equitable's in-force individual life liabilities, about $32 billion, in a transaction the CEO said closed on July 31, 2025.
Bio-Rad reported second-quarter 2025 revenue of $651.6 million, up 2.1% from a year earlier. GAAP net income was $317.8 million, or $11.67 per diluted share, compared with a net loss a year earlier, mainly due to a change in the fair market value of its Sartorius AG investment. Non-GAAP net income fell to $71.0 million, or $2.61 per diluted share, from $88.3 million, or $3.11, and the company raised its non-GAAP operating margin outlook for 2025.
Q2 2025 net sales were $651.6 million, up 2.1% from $638.5 million; currency-neutral sales rose 1.0%.
GAAP net income was $317.8 million, or $11.67 per diluted share, versus a net loss of $(2,165.5) million, or $(76.26) per share, in Q2 2024.
Non-GAAP net income was $71.0 million, or $2.61 per diluted share, versus $88.3 million, or $3.11, a year earlier.
For full-year 2025, non-GAAP operating margin is now expected at approximately 12.0% to 13.0%, up from 10.0% to 12.0%; currency-neutral revenue growth is now expected at approximately 0% to 1.0%, versus a prior range of a 1.0% decline to 1.
Clorox reported fourth-quarter fiscal 2025 net sales up 4% to $2.0 billion and adjusted EPS up 58% to $2.87, helped by incremental ERP-related retailer shipments. For fiscal 2026 it expects net sales down 6% to 10% and adjusted EPS of $5.95 to $6.30, a decline of 18% to 23%, as the ERP shipment benefit reverses.
Q4 net sales rose 4% to $2.0 billion; organic sales rose 8%, with incremental ERP shipments adding about 13 to 14 points
Q4 diluted EPS rose 55% to $2.68 and adjusted EPS rose 58% to $2.87 versus $1.82 a year earlier
FY2026 diluted EPS outlook is $5.60 to $5.95, versus $6.52 in fiscal 2025; adjusted EPS outlook is $5.95 to $6.30 versus $7.72
Net cash provided by operations was $981 million for fiscal 2025, up 41% from $695 million
Illumina reported second-quarter 2025 revenue of $1.06 billion, down 3% from a year earlier on both reported and constant currency bases, while GAAP diluted EPS was $1.49 versus a loss of $12.48 a year earlier. The company raised its full-year 2025 non-GAAP diluted EPS guidance to $4.45 to $4.55 and agreed to acquire SomaLogic from Standard BioTools, a deal expected to close in the first half of 2026.
Q2 2025 revenue of $1.06 billion, down 3% from Q2 2024 on a reported and constant currency basis
GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025; non-GAAP operating margin of 23.8%
FY2025 non-GAAP diluted EPS guidance raised to $4.45 to $4.55, up from $4.20 to $4.30, including about 10 cents from recently passed U.S. R&D tax legislation
Repurchased about 4.5 million shares for $380 million in Q2; about $800 million authorization remaining at quarter end
Matson reported second-quarter 2025 net income of $94.7 million, or $2.92 per diluted share, down from $113.2 million, or $3.31, a year earlier, on revenue of $830.5 million versus $847.4 million. The company said it is raising its full-year outlook, now expecting Ocean Transportation operating income above its early May guidance but moderately below 2024, while it expects third-quarter consolidated operating income to be meaningfully lower than a year earlier.
Diluted EPS was $2.92 versus $3.31; net income was $94.7 million versus $113.2 million.
Operating income was $113.0 million versus $124.6 million; revenue was $830.5 million versus $847.4 million.
China container volume fell 14.6 percent year-over-year in the second quarter amid tariff-related uncertainty.
For full-year 2025, Ocean Transportation operating income is expected to be higher than early May guidance but moderately lower than 2024; third-quarter consolidated operating income is expected to be meaningfully lower than $242.3 million
Corcept reported second quarter 2025 revenue of $194.4 million, up from $163.8 million a year earlier, but net income was $35.1 million versus $35.5 million and diluted earnings per share fell to $0.29 from $0.32. The company modified its 2025 revenue guidance to $850 million to $900 million and said demand outpaced its specialty pharmacy vendor's capacity, which it expects to ease as a second pharmacy comes online.
Q2 2025 revenue $194.4 million vs. $163.8 million in Q2 2024
Net income $35.1 million vs. $35.5 million; diluted EPS $0.29 vs. $0.32
Selling, general and administrative expense $103.9 million vs. $66.9 million a year earlier
2025 revenue guidance modified to $850 million to $900 million; cash and investments $515.0 million at June 30, 2025
Ryan Specialty reported second-quarter 2025 results for the period ended June 30, with total revenue up 23.0% and net income up 5.6%. The company cut its full-year 2025 organic revenue growth guidance to 9.0%-11.0% from 11%-13%, while narrowing its Adjusted EBITDAC margin guidance and declaring a $0.12 quarterly dividend.
Total revenue rose 23.0% year-over-year to $855.2 million; organic revenue growth slowed to 7.1% from 14.2%.
Net income rose 5.6% to $124.7 million; diluted EPS was $0.38 versus $0.37, and adjusted diluted EPS rose 13.8% to $0.66.
Full-year 2025 organic revenue growth guidance was lowered to 9.0%-11.0% from 11%-13.0%; Adjusted EBITDAC margin guidance is now 32.5%-33.0%, from 32.5%-33.5%.
Board declared a $0.12 per share regular quarterly dividend, payable August 26, 2025, to holders of record on August 12, 2025.
Coinbase reported second-quarter 2025 total revenue of $1.5 billion, down 26% from the first quarter, as trading activity fell with lower volatility. Net income was $1.4 billion, but that figure included $1.5 billion in strategic investment gains and a $362 million crypto portfolio gain, while Adjusted Net Income was $33 million and Adjusted EBITDA was $512 million. Shareholders should note the $308 million in operating expenses tied to the data theft incident and the company's Q3 outlook for subscription and services revenue of $665 million to $745 million.
Total revenue was $1.5 billion, down 26% Q/Q; transaction revenue was $764 million, down 39% Q/Q.
Net income was $1.4 billion, versus Adjusted Net Income of $33 million, which excludes $1.5 billion in pre-tax strategic investment gains and a $362 million pre-tax crypto portfolio gain.
Adjusted EBITDA was $512 million, down from $930 million in Q1 2025.
Q3 2025 outlook: subscription and services revenue of $665 million to $745 million; July transaction revenue of approximately $360 million.
Agree Realty reported second-quarter 2025 results and raised its 2025 AFFO per share guidance to $4.29 to $4.32 from $4.27 to $4.30. It also raised its 2025 investment volume guidance to $1.4 billion to $1.6 billion from $1.3 billion to $1.5 billion. Net income per share fell 18.5% to $0.43, while Core FFO and AFFO per share rose, so shareholders get a mixed picture of profit against cash-flow measures.
Q2 2025 net income per share attributable to common stockholders decreased 18.5% to $0.43, from $0.52; net income was $47.3 million, down 10.5%.
Q2 2025 Core FFO per share increased 1.3% to $1.05, and AFFO per share increased 1.7% to $1.06.
2025 AFFO per share guidance raised to $4.29 to $4.32; 2025 investment volume guidance raised to $1.4 billion to $1.6 billion.
Monthly dividend of $0.256 per share declared for June, a 2.4% year-over-year increase; the July dividend is payable August 14, 2025.
Rogers reported second quarter 2025 net sales of $202.8 million, up 6.5% from the prior quarter but down from $214.2 million a year earlier. A net loss of $73.6 million, or $(4.00) per diluted share, reflected $71.8 million of non-cash impairment charges, while adjusted earnings per diluted share were $0.34. The company also announced cost reduction initiatives at its curamik business, with expected charges of $12.0 million to $20.0 million.
Q2 2025 net sales of $202.8 million, up 6.5% sequentially and down from $214.2 million in Q2 2024
GAAP net loss of $73.6 million, or $(4.00) per diluted share, including $71.8 million of non-cash impairment charges and $4.3 million of restructuring expenses
Adjusted EPS of $0.34, up from $0.27 in Q1 2025 and down from $0.69 in Q2 2024
Curamik cost initiatives expected to cut costs by more than $13.0 million annually, with $12.0 million to $20.0 million of expenses; Q3 2025 net sales guidance is $200 million to $215 million
Columbia Sportswear reported second quarter 2025 net sales up 6% to $605.2 million, with a net loss of $10.2 million, or $0.19 per diluted share, narrowed from $0.20 a year earlier. The company gave a limited full year 2025 net sales outlook of $3.33 billion to $3.40 billion and third quarter diluted EPS guidance of $1.00 to $1.20, compared with $1.56 in the prior-year quarter, citing global trade policy uncertainty.
Q2 2025 net sales rose 6% to $605.2 million; operating loss was $23.6 million, versus $23.8 million a year earlier.
Full year 2025 net sales are expected to range from $3.33 billion to $3.40 billion, a decline of 1% to an increase of 1% versus 2024.
Third quarter 2025 diluted EPS is expected at $1.00 to $1.20, compared with $1.56 in the third quarter of 2024.
Board declared a quarterly dividend of $0.30 per share, payable September 4, 2025 to holders of record on August 21, 2025.
Casella Waste Systems reported second-quarter 2025 revenue of $465.3 million, up 23.4%, and Adjusted EBITDA of $109.5 million, up 19.5%, but net income fell to $5.2 million. The company raised its full-year revenue guidance and cut its net income guidance to $8 million to $18 million, while reaffirming Adjusted EBITDA guidance of $410 million to $425 million, so shareholders see stronger sales and cash-flow measures alongside lower profit.
Q2 2025 revenue $465.3 million, up $88.2 million from the same period in 2024; net income $5.2 million, down from $7.0 million
Adjusted EBITDA $109.5 million for the quarter, up 19.5%; six acquisitions completed in the first half with over $90 million in annualized revenue
Fiscal 2025 revenue guidance raised to $1.820 billion to $1.840 billion; net income guidance revised to $8 million to $18 million from $10 million to $25 million
Adjusted EBITDA guidance reaffirmed at $410 million to $425 million; the guidance excludes the pending Mountain State Waste acquisition
Kirby reported second-quarter 2025 diluted earnings per share of $1.67, up from $1.43 a year earlier, on revenue of $855.5 million, up from $824.4 million. Management said that if current softness in trade flows and demand persists, 2025 EPS growth will likely be closer to the low end of the prior 15% to 25% range, which matters to shareholders because it signals weaker expected profit growth for the rest of the year.
Q2 2025 net earnings attributable to Kirby were $94.3 million, or $1.67 per diluted share, versus $83.9 million, or $1.43, in Q2 2024
Q2 2025 revenue was $855.5 million, versus $824.4 million; free cash flow was $22.5 million, versus $90.7 million
If current softness persists, 2025 EPS growth will likely be closer to the lower end of the prior 15% to 25% guidance
Total debt rose to $1,117.8 million at June 30, 2025, from $874.9 million at December 31, 2024
AGCO reported second-quarter 2025 net sales of $2.6 billion, down 18.8% from a year earlier, and reported net income of $4.22 per share versus a loss of $4.92 per share in the prior-year quarter. Adjusted earnings per share fell to $1.35 from $2.53, and the company raised its full-year net sales and earnings per share outlook, with reported quarterly results helped by a $205.5 million income tax benefit.
Q2 2025 net sales were $2.6 billion, down 18.8% year over year and down 22.3% excluding currency translation.
Reported EPS was $4.22 versus $(4.92) a year earlier; adjusted EPS was $1.35 versus $2.53.
Full-year 2025 net sales are now expected at approximately $9.8 billion, with EPS now targeted between $4.75 and $5.00.
On July 9, 2025, the Board authorized a new share repurchase program of up to $1.0 billion of common stock.
BorgWarner reported second quarter 2025 net sales of $3,638 million, up about 1% from a year earlier, and U.S. GAAP net earnings of $1.03 per diluted share, down from $1.39. Adjusted earnings were $1.21 per diluted share, up about 2%, and the company raised its full-year 2025 adjusted earnings per share guidance to $4.45 to $4.65 from $4.00 to $4.45. The board also raised the quarterly dividend 55% to $0.17 per share and increased the share repurchase authorization to $1 billion.
Q2 2025 U.S. GAAP net earnings were $224 million, or $1.03 per diluted share, compared with $315 million, or $1.39, in Q2 2024.
Full-year 2025 net sales guidance raised to $14.0 billion to $14.4 billion; GAAP net earnings guidance set at $3.80 to $3.97 per diluted share.
Quarterly cash dividend increased 55% to $0.17 per share, payable September 15, 2025, to holders of record on September 2, 2025.
Share repurchase authorization increased to $1 billion; the company bought about $108 million of its shares in the second quarter.
Alnylam reported second quarter 2025 total net product revenues of $672 million, up 64% from a year earlier, and raised its full-year 2025 total net product revenue guidance to $2,650 million to $2,800 million from $2,050 million to $2,250 million. The company also posted a GAAP loss from operations of $16.2 million, compared with income of $48.6 million a year earlier, and a GAAP net loss of $0.51 per share versus $0.13 in the prior-year quarter.
Q2 2025 total revenues were $773.7 million, up 17% from $659.8 million in Q2 2024
AMVUTTRA net product revenues were $492 million, up 114%; total TTR net product revenues were $544 million, up 77%
GAAP loss from operations was $16.2 million, versus income of $48.6 million; non-GAAP income from operations fell 31% to $95.5 million
Cost of goods sold rose to $142.0 million from $67.3 million, and GAAP SG&A expenses rose 30% to $323.3 million
Upbound Group reported second-quarter 2025 revenue of $1.16 billion, up 7.5% from a year earlier, and non-GAAP diluted EPS of $1.12, up from $1.04. GAAP diluted EPS fell to $0.26 from $0.61 because of $65.5 million in pre-tax special items, including legal matters. The company raised the midpoint of its full-year 2025 non-GAAP EPS guidance to $4.05 to $4.40 from $4.00 to $4.40.
Q2 2025 consolidated revenue was $1,157.5 million, up 7.5% year over year, helped by the Brigit acquisition.
GAAP net earnings were $15.5 million, down from $33.9 million; GAAP operating profit was $50.7 million, down from $80.7 million.
FY 2025 non-GAAP diluted EPS guidance midpoint raised; Adjusted EBITDA guidance narrowed to $515 million to $535 million from $510 million to $540 million.
Q3 2025 guidance: revenue of $1.05 billion to $1.15 billion and non-GAAP diluted EPS of $0.95 to $1.05.
Peabody reported a second-quarter net loss attributable to common stockholders of $27.6 million, or $0.23 per diluted share, compared with net income of $199.4 million, or $1.42 per share, a year earlier. Revenue fell to $890.1 million from $1,042.0 million, and Adjusted EBITDA fell to $93.3 million from $309.7 million, while the company raised some full-year volume targets and lowered cost targets for three segments. The company also said a Material Adverse Change has occurred under its purchase agreements for the Anglo American Moranbah North acquisition and plans a further update on August 19, 2025.
Q2 2025 net loss attributable to common stockholders of $27.6 million, or $0.23 per diluted share, versus $199.4 million, or $1.42 per share, in Q2 2024
Q2 revenue of $890.1 million versus $1,042.0 million a year earlier; Adjusted EBITDA of $93.3 million versus $309.7 million
Full-year 2025 PRB volume guidance raised by 5 million tons; Seaborne Metallurgical full-year cost guidance lowered by $7 per ton to approximately $118 per ton
Quarterly dividend of $0.075 per share payable September 3, 2025 to holders of record August 14, 2025
Laureate Education reported second-quarter 2025 revenue of $524.2 million, up 5% on a reported basis, and operating income of $193.3 million, up from $166.6 million. Net income fell to $97.4 million from $128.4 million, mainly due to a $25.6 million foreign currency exchange loss, and diluted earnings per share were $0.65 versus $0.83. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, citing more favorable foreign currency rates.
Q2 2025 revenue $524.2 million, up 5% reported and up 10% organic constant currency
Q2 net income $97.4 million vs. $128.4 million a year earlier; diluted EPS $0.65 vs. $0.83
2025 revenue guidance raised by about $55 million to $1,615 million–$1,630 million
2025 Adjusted EBITDA guidance raised by about $16 million to $489 million–$496 million
Terex reported second quarter 2025 net sales of $1.5 billion, up 7.6% from a year earlier, while GAAP diluted EPS fell to $1.09 from $2.08 and adjusted EPS fell to $1.49 from $2.16. The board authorized a new $150 million share repurchase program and the company kept its full-year adjusted EPS outlook of $4.70 to $5.10.
Q2 2025 operating margin was 8.7% (11.0% adjusted), versus 14.0% a year earlier
Aerials net sales fell 17.1% to $607 million; Materials Processing fell 9.0% to $454 million; Environmental Solutions rose 12.9% on a pro forma basis to $430 million
Free cash flow was $78 million, up from $43 million; liquidity was $1.2 billion as of June 30, 2025
Full-year 2025 outlook: net sales $5.3 billion to $5.5 billion, adjusted EPS $4.70 to $5.10, assuming tariffs remain at current rates
CVS Health reported second-quarter 2025 revenue of $98.9 billion, up 8.4%, but GAAP diluted EPS fell to $0.80 from $1.41 after $833 million in litigation charges. The company raised its full-year adjusted EPS guidance to $6.30 to $6.40 while cutting its GAAP EPS guidance to $3.84 to $3.94, so shareholders face a mixed picture of stronger underlying performance and lower reported profit.
Q2 total revenues were $98.9 billion, up from $91.2 billion a year earlier; adjusted EPS was $1.81 versus $1.83
GAAP diluted EPS guidance was revised to $3.84 to $3.94 from $4.23 to $4.43
Adjusted EPS guidance was raised to $6.30 to $6.40 from $6.00 to $6.20
Cash flow from operations guidance was raised to at least $7.5 billion from about $7.0 billion
WESCO International reported second-quarter 2025 net sales of $5.90 billion, up 7.7% from a year earlier, and raised its full-year 2025 organic sales growth outlook while keeping its EPS midpoint unchanged. GAAP diluted EPS fell 10.5% to $3.83, while adjusted diluted EPS rose 5.6% to $3.39 and adjusted EBITDA declined 1.5%, mainly due to lower gross margin from large project wins and higher SG&A expenses.
Q2 net sales $5,899.6 million, up 7.7%; organic sales up 7.2%
GAAP diluted EPS $3.83 vs. $4.28; adjusted diluted EPS $3.39 vs. $3.21
Adjusted EBITDA $394.2 million, down 1.5%; adjusted EBITDA margin 6.7% vs. 7.3%
Full-year 2025 organic sales growth outlook raised; EPS midpoint maintained
Host Hotels & Resorts reported second-quarter 2025 revenue of $1,586 million, up 8.2% from $1,466 million a year earlier, and raised its full-year 2025 guidance for net income and diluted earnings per share. Net income fell 7.0% to $225 million and diluted earnings per share fell 5.9% to $0.32, mainly because of a $47 million decrease in net gains on insurance settlements.
Q2 2025 revenue $1,586 million vs. $1,466 million in Q2 2024 (up 8.2%); diluted EPS $0.32 vs. $0.34 (down 5.9%)
Net income $225 million, down 7.0%, reflecting a $47 million decrease in net gains on insurance settlements
Full-year 2025 net income guidance raised to $601 to $631 million from $512 to $581 million; diluted EPS guidance raised to $0.85 to $0.90 from $0.72 to $0.82
Sold The Westin Cincinnati for $60 million and repurchased $105 million of common stock in Q2 2025
Silgan Holdings reported second quarter 2025 net sales of $1.54 billion, up 11%, and net income of $89.0 million, or $0.83 per diluted share, compared with $0.71 a year earlier. The company cut its full-year 2025 adjusted EPS estimate to $3.85 to $4.05 from $4.00 to $4.20 and lowered its free cash flow estimate to about $430 million, citing lower specialty closures volumes and a recent customer bankruptcy in North American Metal Containers.
Q2 2025 net sales were $1.54 billion, up $157.8 million or 11%, mainly from the Weener acquisition and the pass-through of higher raw material costs.
Q2 2025 net income was $89.0 million, or $0.83 per diluted share, versus $0.71 in Q2 2024; adjusted EPS rose 15% to $1.01.
2025 adjusted EPS estimate was lowered to $3.85 to $4.05 from $4.00 to $4.20.
2025 free cash flow estimate was lowered to about $430 million from about $450 million.
Sun Communities reported a second-quarter net loss from continuing operations of $92.2 million, or $1.23 per diluted share, while net income attributable to common shareholders reached $1.3 billion, or $10.02 per diluted share, after the Safe Harbor Sale. Core FFO per share fell to $1.76 from $1.86 a year earlier, but the company raised its full-year 2025 Core FFO per share guidance to $6.51 to $6.67.
Net loss from continuing operations of $92.2 million ($1.23 per diluted share) versus net income of $32.7 million ($0.21) a year earlier
Net income attributable to common shareholders of $1.3 billion ($10.02 per diluted share), versus $52.1 million ($0.42) a year earlier; Safe Harbor Sale gain of $1.4 billion
Core FFO per share of $1.76 versus $1.86 a year earlier; full-year 2025 Core FFO guidance raised to $6.51 to $6.67
Charles D. Young becomes CEO effective October 1, 2025, succeeding Gary Shiffman
Element Solutions reported second quarter 2025 net sales of $625 million, up 2% on a reported basis and 6% organically, while reported net income fell 49% to $48 million and GAAP diluted EPS fell to $0.20 from $0.38. The company said it recently increased its full year 2025 adjusted EBITDA guidance to $530 million to $550 million, which signals management's view of stronger operating earnings even as GAAP profit declined.
Q2 2025 net sales were $625 million, up 2% reported and 6% organic; Electronics sales rose 12% to $439 million
Reported net income was $48 million versus $93 million a year earlier; adjusted EBITDA was $136 million, up 1%
Full year 2025 adjusted EBITDA guidance is $530 million to $550 million; third quarter adjusted EBITDA is expected at $140 million to $145 million
Company repurchased 0.9 million shares for approximately $19.5 million in Q2; about $562 million remained under its buyback authorization at June 30, 2025
UDR reported second quarter 2025 net income of $0.11 per diluted share, up from $0.08 a year earlier, and FFO of $0.61 per diluted share, up from $0.60. Total revenue rose 2.4% to $425.4 million. The company raised its full-year 2025 FFOA per diluted share and same-store revenue guidance, but lowered its full-year FFO and net income per diluted share guidance, so shareholders see higher FFOA expectations alongside lower FFO expectations.
Q2 2025 FFOA per diluted share was $0.64 versus $0.62 a year earlier and above the $0.61 to $0.63 guidance range; FFO was $0.61 versus $0.60.
Full-year 2025 FFOA per diluted share guidance was raised to $2.49 to $2.55 from $2.45 to $2.55, a $0.02 increase at the midpoint.
Full-year 2025 FFO per diluted share guidance was lowered to $2.42 to $2.48 from $2.45 to $2.55, and net income per diluted share guidance was lowered to $0.53 to $0.59 from $0.56 to $0.66.
Same-store revenue growth guidance was raised to 1.75% to 3.25%, and same-store occupancy was 96.9% for the quarter.
Enact Holdings reported second quarter 2025 GAAP net income of $168 million, or $1.11 per diluted share, down from $184 million, or $1.16, a year earlier, though up from $166 million in the first quarter. Total revenues rose to $304.9 million from $298.8 million a year earlier, while the company raised its full-year 2025 capital return guidance to approximately $400 million.
Adjusted operating income was $174 million, or $1.15 per diluted share, versus $201 million, or $1.27, in Q2 2024.
Total revenues were $304.9 million, compared with $298.8 million in Q2 2024.
Full-year 2025 capital return guidance increased to approximately $400 million, depending on business performance, market conditions and regulatory approvals.
Board declared a quarterly dividend of $0.21 per share, payable September 8, 2025, to holders of record on August 18, 2025.
Mid-America Apartment Communities reported second-quarter 2025 diluted earnings per share of $0.92, up from $0.86 a year earlier, while diluted Core FFO per share fell to $2.15 from $2.22. The company lowered its full-year 2025 earnings per share guidance to a range of $5.25 to $5.49, with a midpoint of $5.37 versus the prior $5.67, and kept its Core FFO midpoint at $8.77.
Q2 2025 diluted EPS was $0.92 versus $0.86 in Q2 2024; six-month EPS was $2.46 versus $2.09.
Q2 2025 diluted Core FFO per share was $2.15 versus $2.22 in Q2 2024.
Full-year 2025 EPS guidance revised to $5.25 to $5.49 from $5.51 to $5.83.
Full-year 2025 Core FFO guidance range narrowed to $8.65 to $8.89 from $8.61 to $8.93; midpoint unchanged at $8.77.
Align Technology reported second quarter 2025 revenue of $1,012.4 million, down 1.6% from a year earlier, while GAAP diluted earnings per share rose to $1.72 from $1.28. The company said Q2 results were below its outlook and announced actions to reduce its workforce and optimize manufacturing, with one-time charges of $150 million to $170 million expected in the second half of 2025.
Q2 2025 revenue was $1,012.4 million, down 1.6% year-over-year and up 3.4% sequentially.
Q2 2025 GAAP diluted EPS was $1.72 versus $1.28 in Q2 2024; non-GAAP diluted EPS was $2.49.
Q3 2025 worldwide revenue is expected to be $965 million to $985 million, down sequentially from Q2.
One-time charges of $150 million to $170 million are expected in the second half of 2025; FY 2025 GAAP operating margin is expected at 13% to 14%.
Ford reported record second-quarter 2025 revenue of $50.2 billion, up 5% year over year, but posted a net loss of $36 million, compared with net income of $1.8 billion a year earlier, mainly due to special charges. The company reinstated full-year 2025 adjusted EBIT guidance of $6.5 billion to $7.5 billion, below the $7.0 billion to $8.5 billion it first gave in February before withdrawing it in May.
Second-quarter revenue was $50.2 billion, up 5%; adjusted EBIT was $2.1 billion, including $0.8 billion of adverse net tariff-related impacts.
Net loss attributable to Ford was $36 million, or $0.01 per diluted share, versus net income of $1.8 billion, or $0.46 per share, a year earlier.
Full-year 2025 guidance: adjusted EBIT of $6.5 billion to $7.5 billion, adjusted free cash flow of $3.5 billion to $4.5 billion, and a net tariff-related headwind of about $2 billion.
Board declared a third-quarter regular dividend of 15 cents per share, payable Sept. 2 to holders of record at the close of business on Aug. 11.
Independence Realty Trust reported second quarter 2025 net income available to common shares of $8.0 million, down from $10.4 million a year earlier, with diluted EPS of $0.03 versus $0.05. Same-store rental and other property revenue rose 1.0% and same-store NOI rose 2.0%, while CFFO per share held at $0.28. The company raised its 2025 full-year EPS guidance to $0.475-$0.535 from $0.19-$0.22, mainly reflecting gains on property sales, and kept its CFFO per share guidance at $1.165-$1.185.
Q2 2025 CFFO was $66.7 million versus $63.6 million a year earlier; CFFO per share was $0.28 in both periods.
Same-store NOI rose 2.0% and same-store average occupancy was 95.3%.
2025 EPS guidance was raised to $0.475-$0.535 from $0.19-$0.22; CFFO per share guidance was unchanged at $1.165-$1.185.
The company is under contract to acquire two Orlando, Florida properties for an aggregate purchase price of approximately $155 million, expected to close in Q3 2025.
Neurocrine Biosciences reported second-quarter 2025 net product sales of $682 million, up 17% year over year, and GAAP diluted earnings per share of $1.06 versus $0.63 a year earlier. The company narrowed its 2025 INGREZZA net product sales guidance to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion, lowering the top of the range, and said a Phase 3 study of valbenazine in schizophrenia did not meet its primary endpoint.
Q2 2025 net product sales were $682 million: INGREZZA $624.4 million and CRENESSITY $53.2 million
GAAP net income was $107.5 million ($1.06 per diluted share) versus $65.0 million ($0.63) in Q2 2024; non-GAAP EPS was $1.65 versus $1.63
INGREZZA 2025 net product sales guidance narrowed to $2.5 billion to $2.55 billion from $2.5 billion to $2.6 billion
Company repurchased $18 million of stock in Q2 2025 and had $332 million remaining under its $500 million program as of June 30, 2025
Magnolia Oil & Gas reported second quarter 2025 net income of $81.0 million, down from $105.1 million a year earlier, and diluted EPS of $0.41 versus $0.51. Total revenues were $319.0 million compared with $336.7 million, while production rose 9% to 98.2 thousand barrels of oil equivalent per day, and the company raised its full-year production growth outlook to about 10%. For shareholders, the weaker revenue and earnings contrast with higher output and continued buybacks and dividends.
Q2 2025 net income was $81.0 million versus $105.1 million, and diluted EPS was $0.41 versus $0.51.
Total revenues were $319.0 million versus $336.7 million; adjusted EBITDAX was $223.2 million versus $246.1 million.
Full-year 2025 production growth guidance was raised to about 10% from 7% to 9%, with D&C capital maintained at $430 million to $470 million.
The company repurchased 2.2 million shares for $48.7 million in the quarter and closed about $40 million of bolt-on acquisitions in late June and early July.
Verisk reported second-quarter 2025 revenue of $773 million, up 7.8%, and raised its full-year 2025 revenue and adjusted EBITDA outlook. Net income fell 17.7% to $253 million, mainly because the prior-year period included gains on business sales and an early debt extinguishment. The company also agreed on July 29, 2025 to acquire AccuLynx for $2.35 billion in cash, subject to customary closing conditions including regulatory approval.
Q2 2025 revenue of $773 million, up 7.8%; adjusted EBITDA of $445 million, up 11.9%
Net income of $253 million, down 17.7%; diluted GAAP EPS of $1.81, down 15.8%, versus prior-year gains
Full-year 2025 revenue guidance raised to $3,090 - $3,130 million from $3,030 - $3,080 million; diluted adjusted EPS guidance now $6.80 - $7.00 from $6.80 - $7.10
Agreed to acquire AccuLynx for $2.35 billion in cash on July 29, 2025; acquired SuranceBay on July 17, 2025 for $162.5 million
Steve Madden reported second quarter 2025 revenue of $559.0 million, up 6.8%, but a GAAP net loss attributable to the company of $39.5 million, or $0.56 per diluted share, compared with net income of $35.4 million a year earlier. The company cited new tariffs on imported goods and did not provide 2025 financial guidance, while its Board declared a $0.21 quarterly dividend.
Revenue was $559.0 million, up from $523.6 million, with wholesale revenue down 6.4% to $360.6 million and direct-to-consumer revenue up 43.3% to $195.5 million.
GAAP loss from operations was $40.3 million, compared with income of $46.9 million a year earlier; adjusted income from operations was $22.6 million.
Adjusted diluted earnings per share were $0.20, compared with $0.57 a year earlier.
No 2025 financial guidance was given due to macroeconomic uncertainty tied to tariffs; the $0.21 dividend is payable September 23, 2025 to holders of record on September 12, 2025.
Humana reported second-quarter 2025 GAAP EPS of $4.51, down from $5.62 a year earlier, and adjusted EPS of $6.27, down from $6.96. Revenue rose to $32.4 billion from $29.5 billion. The company cut its full-year 2025 GAAP EPS guidance to about $13.77 from about $14.68 while raising adjusted EPS guidance to about $17.00 from $16.25 and revenue guidance to at least $128 billion, so headline measures moved in different directions.
2Q25 GAAP EPS was $4.51 versus $5.62 in 2Q24; adjusted EPS was $6.27 versus $6.96.
2Q25 Insurance segment benefit ratio was 89.9 percent, in line with the previously disclosed expectation of approximately 90 percent.
FY 2025 individual Medicare Advantage membership decline is now expected to be up to 500,000, down from approximately 550,000 previously.
CenterWell Primary Care now expects FY 2025 net patient growth of 50,000 to 70,000, up from 30,000 to 50,000.
Ashland reported preliminary third-quarter fiscal 2025 sales of $463 million, down 15 percent from $544 million a year earlier, and a net loss of $742 million, or $(16.21) per diluted share, mainly due to a non-cash goodwill impairment charge of $706 million. The company also narrowed its full-year fiscal 2025 outlook to sales of $1.825 billion to $1.850 billion and Adjusted EBITDA of $400 million to $410 million, with current assumptions weighted toward the lower end. For shareholders, the large charge and weaker sales and Adjusted EBITDA are the key takeaways, and the results remain preliminary until the Form 10-Q is filed.
Q3 sales of $463 million, down 15 percent; Portfolio Optimization reduced sales by about $53 million, or 10 percent
Net loss of $742 million, or $(16.21) per diluted share, including the $706 million goodwill impairment charge
Adjusted EBITDA of $113 million, down 19 percent from $139 million a year earlier
Full-year fiscal 2025 outlook narrowed to sales of $1.825 billion to $1.850 billion and Adjusted EBITDA of $400 million to $410 million
O-I Glass reported a second-quarter 2025 net loss of $0.03 per diluted share, compared with earnings of $0.36 a year earlier, mostly due to $108 million in restructuring and asset impairment charges tied to halting the MAGMA program. Adjusted EPS rose to $0.53 from $0.44, and the company raised its full-year 2025 adjusted EPS guidance to $1.30 to $1.55 from $1.20 to $1.50.
Q2 2025 net loss attributable to the company of $0.03 per diluted share, versus $0.36 in Q2 2024; adjusted EPS $0.53 versus $0.44
Net sales of $1.7 billion, consistent with the prior year, with shipment volume down about 3 percent
Full-year 2025 adjusted EPS guidance raised to $1.30 to $1.55; free cash flow guidance unchanged at $150 to $200 million
Charges of approximately $45 million expected in Q3 2025 from the planned closure of one Americas plant and suspension of one furnace
Chemed reported second-quarter 2025 revenue up 3.8% to $618.8 million, but GAAP diluted earnings per share fell 23.2% to $3.57. The company cut its full-year 2025 EPS guidance to $22.00 to $22.30 from $24.95 to $25.45, citing a larger Medicare Cap billing limitation at VITAS, and said VITAS CEO Nicholas M. Westfall is resigning, with Joel L. Wherley to succeed him.
Q2 2025 revenue rose 3.8% to $618.8 million; GAAP diluted EPS was $3.57, down 23.2%, and adjusted diluted EPS was $4.27, down 21.9%.
Full-year 2025 EPS guidance revised to $22.00 to $22.30, versus the previously issued $24.95 to $25.45.
VITAS estimates a $19 million Florida Medicare Cap billing limitation for the cap year ending September 30, 2025, and accrued $16.4 million in Q2 2025.
Nicholas M. Westfall resigns as Chairman and CEO of VITAS effective July 29, 2025, and will remain an Executive Vice President through December 1, 2025; Joel L. Wherley will succeed him as VITAS CEO.
American Assets Trust reported second-quarter 2025 results that showed lower per-share funds from operations (FFO) and net income than a year earlier, while the company raised the low end of its 2025 FFO guidance. The guidance change is modest, but the quarterly decline in core per-share earnings is the main point for shareholders to weigh.
Q2 2025 FFO per diluted share, excluding lease termination fees and litigation income, was $0.51, down from $0.60 in Q2 2024
Q2 2025 net income available to common stockholders was $5.5 million, or $0.09 per diluted share, versus $11.9 million in Q2 2024
2025 FFO per diluted share guidance raised to $1.89 to $2.01 from $1.87 to $2.01, a midpoint of $1.95, about 1% higher
Same-store cash net operating income fell 0.3% in Q2 2025 year over year, while six-month same-store cash NOI rose 1.4%
Werner Enterprises reported second-quarter 2025 results, with total revenues of $753.1 million, down 1% from a year earlier. GAAP net income attributable to Werner rose 366% to $44.1 million, mainly because of a $45.7 million net liability reversal tied to a Texas Supreme Court ruling, while non-GAAP adjusted diluted EPS fell 36% to $0.11. The company also narrowed its 2025 net capital expenditure guidance to $145 million to $185 million.
Total revenues were $753.1 million, down $7.7 million or 1% year over year; Logistics revenue rose 6%, while Truckload Transportation Services revenue fell 4%.
GAAP diluted EPS was $0.72, up from $0.15; the company cited a $45.7 million net liability reversal from the Texas Supreme Court ruling as a non-GAAP adjustment.
Non-GAAP adjusted diluted EPS was $0.11, down 36% from $0.17, and adjusted operating margin was 2.2%, down 60 basis points.
2025 net capital expenditure guidance was lowered to $145 million to $185 million from $185 million to $235 million, and the TTS year-end truck count guidance was narrowed to 1% to 4% from 1% to 5%.
W. P. Carey reported second quarter 2025 revenues of $430.8 million, up 10.5% from a year earlier, and AFFO of $1.28 per diluted share, up 9.4%. The company raised its full-year 2025 AFFO guidance to $4.87 to $4.95 per diluted share, but net income attributable to the company fell 64.2% to $51.2 million, mainly due to a $69.0 million mark-to-market loss on its Lineage shares.
Q2 2025 revenues, including reimbursable costs, were $430.8 million, up 10.5% from $389.7 million in Q2 2024.
AFFO was $1.28 per diluted share, up from $1.17; net income attributable to W. P. Carey was $51.2 million, or $0.23 per diluted share, versus $142.9 million in Q2 2024.
2025 AFFO guidance was raised to $4.87 to $4.95 per diluted share, based on investment volume of $1.4 billion to $1.8 billion.
Quarterly dividend was increased to $0.900 per share, a 3.4% rise from the 2024 second quarter, and paid on July 15, 2025.
Franklin Electric reported second quarter 2025 net sales of $587.4 million, up 8% from the prior year, and operating income of $88.1 million, up 11%. It kept its full-year 2025 guidance but said it expects a non-cash pension plan termination in the third quarter that will reduce EPS by approximately $1.00 per share, which is not included in that guidance.
Q2 net sales $587.4 million vs $543.3 million; operating income $88.1 million vs $79.1 million; operating margin 15.0%
Q2 diluted EPS $1.31 vs $1.26 in Q2 2024
Full-year 2025 guidance maintained: sales $2.09 billion to $2.15 billion; EPS $3.95 to $4.25
Third-quarter US Pension Plan termination expected to have a non-cash EPS impact of approximately $1.00 per share; operating cash flow for first six months was $32.0 million vs $35.0 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.